Evidence-based articles on weight maintenance, GLP-1 medications, and metabolic health
Good first reads if you are comparing Ozempic, Wegovy, Mounjaro or oral GLP-1 treatment and want a physician-led overview before booking.
If you’ve tried everything and still can’t lose weight, it doesn’t automatically mean you lack willpower. A physician explains why biology and context matter-and when to seek support.
Read article →Ozempic and Wegovy contain semaglutide; Mounjaro contains tirzepatide. Here are the practical differences in approved indications, expected benefits, common side effects, and key safety warnings.
Read article →Oral semaglutide changes the conversation about GLP-1 treatment, but tablets are not automatically simpler. Here is what patients need to know.
Read article →The FDA warning was about safety reporting, not proof that semaglutide caused deaths. Here is why medical follow-up matters during GLP-1 treatment.
Read article →Articles for people already using GLP-1 medication, thinking about stopping, restarting after a break, or trying to avoid weight regain.
Most people should not stop Ozempic or Wegovy casually. A structured framework for tapering, monitoring, and protecting weight-loss results.
Read article →A physician explains what is known, and what is not known, about restarting Ozempic, Wegovy, or Mounjaro after a break.
Read article →STEP 4 showed that stopping semaglutide leads to rapid, significant weight regain for most people. A physician explains the chronic disease framing: and what it actually means for your treatment plan.
Read article →Weight regain after Ozempic or Wegovy is common: but not inevitable. A practical, evidence-based six-step protocol for the critical 20-week window after GLP-1 therapy ends.
Read article →A major Oxford meta-analysis found weight returns four times faster after stopping GLP-1 medications than after stopping diet and exercise alone. Here's what that means: and what actually helps.
Read article →Two-thirds of people who stop GLP-1 medications regain significant weight. A physician unpacks the biology behind the 67% statistic: set point defence, ghrelin surge, metabolic adaptation: and what genuinely shifts the odds.
Read article →More than 40% of weight lost on semaglutide returns within 28 weeks of stopping. Here's what the STEP-10 data actually shows: and what genuinely helps minimise rebound.
Read article →Stopping Ozempic triggers a ghrelin surge, metabolic adaptation, and muscle loss. A doctor explains what happens system by system, week by week: and what to do about it.
Read article →Weeks 3-6 after stopping GLP-1 medications, appetite surges with unexpected ferocity. A physician explains the triple hormonal threat: ghrelin, leptin, PYY: and how to navigate it.
Read article →What to read when weight loss slows, appetite changes, or the treatment plan needs medical review rather than guesswork.
Weight-loss plateaus on GLP-1 therapy are usually biological adaptation, not personal failure. Here is what to reassess before changing treatment.
Read article →Muscle, resistance training, facial changes, and the practical side of keeping weight loss healthy.
Up to 39% of weight lost on semaglutide is lean mass, not fat. A physician explains exactly why resistance training is a mandatory co-prescription: and how to structure it for maximum protection.
Read article →25-39% of weight lost on semaglutide is lean tissue, not fat. Here's what the research actually shows about muscle loss on Ozempic: and the evidence-based strategies to prevent it.
Read article →Hollowed cheeks, loose skin, sunken eyes: "Ozempic face" is real, but it's not a drug side effect. A physician explains the biology of facial fat loss on GLP-1 medications and what actually prevents it.
Read article →Plain-language reviews of important GLP-1 research, including cardiovascular outcomes and emerging observational findings.
The SELECT trial enrolled 17,604 people and found a 20% reduction in major cardiovascular events with semaglutide. A physician explains what the HR 0.80 result actually means: and what the trial didn't prove.
Read article →A cautious physician explanation of a Penn Medicine observational study: lower observed diagnosis odds are not the same as proving cancer prevention.
Read article →